


Human Anti-B. Pertussis IgG ELISA Kit, Cat# 960-110-PHG

Human Anti-B. Pertussis IgG ELISA kit | Quantitative | Standards 0-150 u/ml | Sample=100 ul (diluted); 110 min assay

**Human Anti- B. Pertussis IgG ELISA Kit Features**

- B. Pertussis antigens (Fha, Toxin, and LPS) Pre-coated, stabilized, ready-to-use 96-well strip plate, suitable for multiple runs over 6-9 months.
- Convenient, stable, liquid calibrators: A (-ve control @ 1 u/ml); B (cut-off control @ 20 u/ml); C (weak positive at 45 u/ml) and D (positive control @ 150 u/ml) containing anti-B. Pertussis IgG
- 100ul samples diluted 1:101 or more; 110 min room temp assay
- Qualitative (-ve or +ve) or quantitative methods;
- Contains all necessary reagents. Stability ~12 months

This kit is for measuring anti-B. Pertussis IgG in human serum or plasma samples. For in vitro research use only.

Assay Procedure: Allow all reagents to reach room temperature. Arrange and label required number of strips.

- Step 1.** Pipet 100 ul each of pre-diluted standards, samples (diluted 1:101 or more). Mix gently and incubate at room temp for 60 min.
Step 2. Aspirate and wash 3X. Add 100 ul of antibody-HRP Conjugate to all wells, mix gently and incubate at room temp for 30 min.
Step 3. Aspirate and wash 4X. Add 100 ul of TMB Substrate solution to all wells, mix gently, and incubate at room temp for 20 min.
Step 4. Pipet 100 ul of stop solution into each well and mix gently (blue color turns yellow). Measure absorbance at 450 nm. Determine antibody concn in each sample using the calibrators (results are expressed as positive or negatives or in units/ml).

Interpretation of Results

Negative: <18 u/ml Equivocal: 18-22 u/ml; Positive: >22

Performance Characteristics

Intra-Assay-Precision:	5.0 %	Inter-Assay-Precision	4.3 %	Inter-Lot-Precision	2,6 – 4.5 %
Analytical Sensitivity:	0,98 U/mL	Recovery	106 – 114 %	Linearity	78 – 124 %
Cross-Reactivity:	No cross-reactivity to RSV, Adenovirus and Parainfluenza IgG				
Interferences:	No interferences to bilirubin up to 0.3 mg/mL, hemoglobin up to 8.0 mg/mL und triglycerides up to 5.0 mg/mL				
Clinical Specificity:	84 %	Clinical Sensitivity:	100 %		

General Information

Pertussis, also known as the whooping cough, is a highly contagious disease caused by the bacterium *Bordetella pertussis*. It derived its name from the "whoop" sound made from the inspiration of air after a cough. Despite generally high coverage with the DTP and DTaP vaccines, pertussis is one of the leading causes of vaccine-preventable deaths world-wide. Ninety percent of all cases occur in the Third World. It is transmitted by airborne infection. The gram negative *Coccobacillus* produces a series of biologically active molecules. The different compounds appear either during the pathogenesis or during the process of immunization against pertussis and show different effects. A characterization has been made for the pertussis toxin (pt), the filamentary haemagglutinine (fha) and different lipopolysaccharides (lps). Pertussis shows a high rate of transmission (rates of infection of over 90 % have been found for non-vaccinated household members) and can cause severe diseases, especially for very young children. From 10749 patients under one year between 1980 and 1989 69 % were brought into hospital, 22 % suffered from pneumonia, 0.9 % showed an Encephalopathy and 0.6 % died. For older children and adults (including already vaccinated persons) the infection may be observed by an unspecified bronchitis or inflammation of the upper respiratory tracts. Even asymptomatic cases are quite common. The serological response following pertussis disease or immunization with pertussis vaccine has been measured with agglutination assays, precipitins, complement fixation and enzyme-linked immunosorbent assay (ELISA). Enzyme-linked immunosorbent assays, in which *Bordetella* antigen (containing toxin, FHA and LPS and standardized in U/ml) is bound to a solid phase support, are sensitive, easy to perform and can be used both to determine seropositivity with a single serum and to indicate recent *Bordetella* infection by determination of IgM and IgA..

B. pertussis vaccine was first developed in 1920 using whole bacterium. In 1942, the whole-cell pertussis vaccine was combined with diphtheria and tetanus toxoids to generate the first DTP combination vaccine. **Whole cell vaccines** have some side effects. **Acellular pertussis vaccine** consisting of purified haemagglutinins (HAs: filamentous HA and leucocytosis-promoting-factor HA), which are secreted by *B. pertussis* into the culture medium are being using alone or in combination with DTaP (aP represents acellular vaccine).

ADI Human Anti-B. Pertussis IgG Antibody ELISA Test Kit has been designed for the detection of specific IgG class antibodies against *B. pertussis* in serum and plasma.

Related ELISA kits

Human: #960-100-PHA (anti-IgA); #960-110-PHG (anti-IgG); #960-120-PHM (anti-IgM)

Mouse: #960-130-PHG (anti-IgG); # 960-140-PHM (anti-IgM)

rev 90830A

India Contact:**Life Technologies (India) Pvt. Ltd.**

306, Aggarwal City Mall, Opposite M2K Pitampura, Delhi – 110034 (INDIA). Ph: +91-11-42208000, 42208111, 42208222, Mobile: +91-9810521400, Fax: +91-11-42208444

Email: customerservice@lifetechindia.com Website: www.lifetechindia.com